M&A Deal Summary

Excellence Health Acquires Tumentia Research

On October 8, 2017, Excellence Health acquired life science company Tumentia Research for 1.2B USD

Acquisition Highlights
  • This is Excellence Health’s 2nd transaction in the Life Science sector.
  • This is Excellence Health’s largest (disclosed) transaction.
  • This is Excellence Health’s 1st transaction in Canada.
  • This is Excellence Health’s 1st transaction in Quebec.

M&A Deal Summary
Date 2017-10-08
Target Tumentia Research
Sector Life Science
Buyer(s) Excellence Health
Deal Type Add-on Acquisition
Deal Value 1.2B USD

Target

Tumentia Research

Montreal, Quebec, Canada
Tumentia is a pharmaceutical company focused on the development of new therapies for cancer patients. The company was founded by graduates of the Concordia University in Montreal, Canada & the University of Wyoming in 2014.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Excellence Health

New York, New York, United States
Category Company
Sector Life Science
DESCRIPTION

Excellence Health, Inc. is a pharmaceutical company that operates focuses on development and commercialization of drugs for patients and healthcare centers. Excellence Health, Inc. is headquartered in New York, New York.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2017) 2 of 2
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-07-08 Insanabilis Research

San Francisco, California, United States

Insanabilis Research LLC is a bio pharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are currently no or limited treatment options. is headquartered in San Francisco, California.

Buy $460M
Mergr

Product

Company

Legal